Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.34
-0.01 (-0.07%)
At close: Feb 20, 2026, 4:00 PM EST
14.33
-0.01 (-0.05%)
After-hours: Feb 20, 2026, 7:10 PM EST
Amicus Therapeutics Revenue
In the year 2025, Amicus Therapeutics had annual revenue of $634.21M with 20.05% growth. Amicus Therapeutics had revenue of $185.21M in the quarter ending December 31, 2025, with 23.72% growth.
Revenue (ttm)
$634.21M
Revenue Growth
+20.05%
P/S Ratio
7.10
Revenue / Employee
$1,270,962
Employees
499
Market Cap
4.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 634.21M | 105.92M | 20.05% |
| Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
| Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
| Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
| Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
| Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
| Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
| Dec 31, 2018 | 91.25M | 54.32M | 147.08% |
| Dec 31, 2017 | 36.93M | 31.97M | 644.86% |
| Dec 31, 2016 | 4.96M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 1.22M | 861.00K | 237.19% |
| Dec 31, 2013 | 363.00K | -18.05M | -98.03% |
| Dec 31, 2012 | 18.41M | -3.02M | -14.10% |
| Dec 31, 2011 | 21.43M | 20.51M | 2,224.73% |
| Dec 31, 2010 | 922.00K | -63.44M | -98.57% |
| Dec 31, 2009 | 64.36M | 49.39M | 330.00% |
| Dec 31, 2008 | 14.97M | 13.18M | 738.96% |
| Dec 31, 2007 | 1.78M | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.05B |
| TG Therapeutics | 531.90M |
| NewAmsterdam Pharma Company | 22.50M |
| CG Oncology | 2.17M |
| Crinetics Pharmaceuticals | 1.54M |
FOLD News
- 13 hours ago - Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 17 days ago - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - GlobeNewsWire
- 18 days ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
- 2 months ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 2 months ago - BioMarin: Amicus Buyout Sparks My Enthusiasm - Seeking Alpha
- 2 months ago - BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. - Barrons
- 2 months ago - BioMarin to Buy Amicus Therapeutics for $4.8 Billion - WSJ
- 2 months ago - BioMarin to acquire Amicus Therapeutics for $4.8 Billion - Reuters